Stoke Therapeutics Valuation
| STOK Stock | USD 10.68 0.05 0.47% |
At this time, the company appears to be undervalued. Stoke Therapeutics has a current Real Value of $13.32 per share. The regular price of the company is $10.68. Our model measures the value of Stoke Therapeutics from inspecting the company fundamentals such as Current Valuation of 328.79 M, shares owned by insiders of 4.60 %, and Return On Equity of -0.52 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Stoke Therapeutics' valuation include:
Price Book 2.4371 | Enterprise Value | Enterprise Value Ebitda (3.62) | Price Sales 33.7865 | Enterprise Value Revenue 19.6372 |
Undervalued
Today
Please note that Stoke Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Stoke Therapeutics is based on 3 months time horizon. Increasing Stoke Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Stoke Therapeutics' intrinsic value may or may not be the same as its current market price of 10.68, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.68 | Real 13.32 | Target 22.75 | Hype 10.64 |
The intrinsic value of Stoke Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Stoke Therapeutics' stock price.
Estimating the potential upside or downside of Stoke Therapeutics helps investors to forecast how Stoke stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Stoke Therapeutics more accurately as focusing exclusively on Stoke Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Stoke Therapeutics' intrinsic value based on its ongoing forecasts of Stoke Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Stoke Therapeutics' closest peers.
Stoke Therapeutics Cash |
|
Stoke Valuation Trend
Knowing Stoke Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Stoke Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Stoke Therapeutics Total Value Analysis
Stoke Therapeutics is at this time estimated to have valuation of 328.79 M with market capitalization of 565.69 M, debt of 2.06 M, and cash on hands of 275.63 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Stoke Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
328.79 M | 565.69 M | 2.06 M | 275.63 M |
Stoke Therapeutics Investor Information
About 95.0% of the company shares are owned by institutional investors. The book value of Stoke Therapeutics was at this time reported as 4.38. The company has Price/Earnings To Growth (PEG) ratio of 0.27. Stoke Therapeutics recorded a loss per share of 2.08. The entity had not issued any dividends in recent years. The firm had 1:9 split on the 6th of June 2019. Based on the key indicators related to Stoke Therapeutics' liquidity, profitability, solvency, and operating efficiency, Stoke Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Stoke Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Stoke Therapeutics has an asset utilization ratio of 3.85 percent. This suggests that the Company is making $0.0385 for each dollar of assets. An increasing asset utilization means that Stoke Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Stoke Therapeutics Ownership Allocation
The majority of Stoke Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Stoke Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Stoke Therapeutics. Please pay attention to any change in the institutional holdings of Stoke Therapeutics as this could imply that something significant has changed or is about to change at the company.Stoke Therapeutics Profitability Analysis
The company reported the previous year's revenue of 8.78 M. Net Loss for the year was (104.7 M) with profit before overhead, payroll, taxes, and interest of 16.74 M.About Stoke Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Stoke Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Stoke Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Stoke Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Stoke Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Stoke Therapeutics. We calculate exposure to Stoke Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Stoke Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 10.1 M | 10.6 M | |
| Pretax Profit Margin | (13.71) | (14.40) | |
| Operating Profit Margin | (15.03) | (15.78) | |
| Net Loss | (13.71) | (14.40) | |
| Gross Profit Margin | 0.64 | 0.58 |
Stoke Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Stoke Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 44 M |
Stoke Therapeutics Current Valuation Indicators
Stoke Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Stoke Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Stoke Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Stoke Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Stoke Therapeutics' worth.When determining whether Stoke Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stoke Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Stoke Therapeutics Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stoke Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share | Quarterly Revenue Growth 0.479 | Return On Assets | Return On Equity |
The market value of Stoke Therapeutics is measured differently than its book value, which is the value of Stoke that is recorded on the company's balance sheet. Investors also form their own opinion of Stoke Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Stoke Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stoke Therapeutics' market value can be influenced by many factors that don't directly affect Stoke Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stoke Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.